NCT03348228 is a NA clinical trial of Hydroxycitrate (HCA) in Nephrolithiasis, sponsored by NYU Langone Health.

Who is sponsoring NCT03348228?

NCT03348228 is sponsored by NYU Langone Health.

What drugs are being tested in NCT03348228?

Interventions in NCT03348228: Hydroxycitrate (HCA).

What condition does NCT03348228 study?

NCT03348228 studies Nephrolithiasis.

Is NCT03348228 still recruiting?

NCT03348228 is currently completed. Last updated 26 January 2022.

Last reviewed 2022-01-26 · How we verify

NCT03348228

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Hydroxycitrate on Urine Chemistry

Completed NA Last updated 26 January 2022

What this trial tests

NA trial testing Hydroxycitrate (HCA) in Nephrolithiasis in 18 participants. Completed in 15 December 2020.

Timeline

4 October 2018

Primary endpoint
15 December 2020

15 December 2020

Quick facts

Lead sponsor	NYU Langone Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	4 October 2018
Primary completion	15 December 2020
Estimated completion	15 December 2020
Sites	1 location across United States

Drugs / interventions tested

Hydroxycitrate (HCA)

Conditions studied

Nephrolithiasis — all drugs for Nephrolithiasis →

Sponsor

NYU Langone Health — full company profile →

Who can join

18 and older, any sex, with Nephrolithiasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hydroxycitrate (HCA) is a compound extracted from the fruit, Garcinia Cambogia. Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. There has been recent evidence that hydroxycitrate is a potent inhibitor of calcium oxalate crystal growth and can lead to the dissolution of the crystals. The purpose of this research study is to study the effect of Hydroxycitrate (HCA) supplements on HCA urinary excretion and on urine chemistries in kidney stone formers and normal subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lipogenesis inhibitors: therapeutic opportunities and challenges.
Batchuluun B, Pinkosky SL, Steinberg GR. · · 2022 · cited 260× · PMID 35031766 · DOI 10.1038/s41573-021-00367-2

Verify or expand the search:

Other recruiting trials for Nephrolithiasis

Currently open trials in the same condition.

NCT07360353 — Comparison Between Different Types of Flexible Ureteroscopes · NA · recruiting
NCT07261995 — Comparison of Extracorporeal Shock Wave Lithotripsy Versus Retrograde Intrarenal Surgery in the Management of Renal Calc · NA · recruiting
NCT07138872 — Hemodynamic Effects of Surgical Position in Prone vs. Supine Percutaneous Nephrolithotomy · NA · recruiting
NCT06989320 — Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease · NA · recruiting
NCT07058402 — RIRS With Flex Suction Sheath vs. PCNL for 2-3 cm Renal Stones · NA · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03348228 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 26 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03348228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing